ArticleDigital health
Retrospective analysis of characteristics of Tami users, a digital patient companion for inflammatory bowel disease.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Inflammatory bowel disease (IBD) is a chronic condition causing gastrointestinal inflammation. Digital health tools like the Tami app support symptom tracking, medication adherence, and personalized care. This study examines demographics, clinical characteristics, medication use, and symptom and patient-reported outcome (PRO) tracking behaviors among Tami app users in Germany. Methods: This retrospective analysis included data from 2059 users aged ≥18 who registered between June 2023 and December 2024. Demographics, clinical characteristics, medication usage, and symptom/PRO tracking behavior were assessed. Group differences were analyzed using chi-square tests. Medications were categorized as conventional (aminosalicylates, azathioprine, methotrexate, corticosteroids, calcineurin inhibitors), advanced (biologics, small molecules), or other (painkillers, antidiarrheals, and vitamins/supplements). Results: Of the 2059 users (mean age: 34.5 years; 73.8% female), 49.4% had ulcerative colitis (UC) and 49.2% had Crohn's disease (CD). Conventional therapies were used by 60.0% and advanced therapies by 57.1%. CD patients were more likely to use advanced therapies (70.0%) than conventional treatments (43.5%) (χ Conclusion: The Tami app is primarily used by younger, female IBD patients. Symptom tracking is highest among younger and recently diagnosed users. These findings underscore the app's potential as a digital tool to support IBD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.